HeartBeam (BEAT) announced a commercial partnership with ClearCardio. In addition to serving as HeartBeam’s first commercial customer, ClearCardio also plans to make an investment in HeartBeam. The partnership includes an initial staged rollout and plans for broader expansion to thousands of members across multiple U.S. geographies. ClearCardio will incorporate HeartBeam’s synthesized 12-lead ECG technology into the program for arrhythmia assessment. The initial agreement with ClearCardio is structured as a letter of intent, outlining the commercial terms and a collaborative rollout plan, including a subscription fee per patient. During the initial deployment phase, HeartBeam and ClearCardio intend to negotiate and execute a definitive agreement.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAT:
- HeartBeam (NASDAQ: BEAT) Upgraded to Buy as New Joseph Gunnar Report Raises Price Target
- HeartBeam (NASDAQ: BEAT) Showcased for Advancing Innovative ECG Platform
- HeartBeam (NASDAQ: BEAT) Highlighted Among Medical Device Innovators as FDA Clearances Set Tone for New Year
- HeartBeam files $100M mixed securities shelf
- HeartBeam (NASDAQ: BEAT) Appoints Bryan Humbarger as Chief Commercial Officer